| Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study Y Du, M Ter-Minassian, L Brais, N Brooks, A Waldron, JA Chan, X Lin, ... Endocr Relat Cancer 23 (8), 587-94, 2016 | 23 | 2016 |
| Simultaneous fixed and random effects selection in finite mixture of linear mixed‐effects models Y Du, A Khalili, JG Nešlehová, RJ Steele Canadian Journal of Statistics 41 (4), 596-616, 2013 | 18 | 2013 |
| Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1 Y Dauvilliers, E Mignot, R del Río Villegas, Y Du, E Hanson, Y Inoue, ... New England Journal of Medicine 389 (4), 309-321, 2023 | 13 | 2023 |
| A moment-based test for extreme-value dependence Y Du, J Nešlehová Metrika 76 (5), 673-695, 2013 | 7 | 2013 |
| A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints Y Zhao, R Tang, Y Du, Y Yuan Biometrics 79 (2), 1459-1471, 2023 | 3 | 2023 |
| Previously unrecognized links between statistical dependence and some common modes of convergence Y Du, C Hundt, DB Wolfson The American Statistician, 55-60, 2011 | 1 | 2011 |
| Impact of the Oral Orexin Receptor 2 Agonist TAK-994 on Sustained Attention in Patients with Narcolepsy Type 1: Exploratory Results from a Phase 2 Study (P11-9.012) Y Dauvilliers, G Plazzi, E Koundourakis, Y Du, C von Hehn, D Volfson, ... Neurology 102 (17_supplement_1), 5396, 2024 | | 2024 |
